Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Public-private partnerships: an overview.

Roy Widdus1

  • 1Initiative on Public-Private Partnerships for Health (IPPPH), Global Forum for Health Research, Geneva, Switzerland. roy.widdus@globalhealthfutures.net

Transactions of the Royal Society of Tropical Medicine and Hygiene
|August 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vaccine mandates, public trust, and vaccine confidence: understanding perceptions is important.

Journal of public health policy·2018
Same author

Understanding 'perceptions' is critical for all vaccination efforts, not only polio eradication.

Journal of public health policy·2017
Same author

Vaccine innovation done differently.

Bulletin of the World Health Organization·2010
Same author

Facing the challenge: the symposium in context.

Transactions of the Royal Society of Tropical Medicine and Hygiene·2005
Same author

Public-private partnerships for health require thoughtful evaluation.

Bulletin of the World Health Organization·2003
Same author

Estimation of "needs" and "probable uptake" for HIV/AIDS preventive vaccines based on possible policies and likely acceptance (a WHO/UNAIDS/IAVI study).

Vaccine·2003

Public-private partnerships (PPPs) are crucial for developing and delivering medicines for neglected diseases. Studies show that access partnerships offer significant benefits with minimal drawbacks, especially for tropical disease treatments.

Area of Science:

  • Global Health
  • Pharmaceutical Policy
  • Health Economics

Background:

  • Commercial development of medicines for developing world diseases is often unattractive due to low-income populations.
  • Public-private partnerships (PPPs) have emerged as a key strategy to address this challenge.
  • PPPs combine diverse expertise and resources to accelerate drug development and delivery.

Purpose of the Study:

  • To evaluate the performance and impact of public-private partnerships (PPPs) in global health.
  • To analyze the effectiveness of different types of PPPs, specifically product development (PD PPPs) and access (Access PPPs).
  • To assess the benefits and side effects of Access PPPs, particularly for tropical diseases.

Main Methods:

  • Monitoring and analysis of public-private partnerships (PPPs) over the last decade.

Related Experiment Videos

  • Categorization of PPPs into product development and access-focused initiatives.
  • Conducting studies specifically on the performance of Access PPPs.

    • Main Results:

    • PPPs have grown significantly in number and diversity over the past 10 years.
    • PPPs tend to fall into two main categories: product development and improving access.
    • Studies on Access PPPs indicate substantial benefits and very few adverse effects, especially for tropical diseases.

    Conclusions:

    • Public-private partnerships are an increasingly vital mechanism for addressing health disparities.
    • Access PPPs demonstrate a highly effective model for delivering essential medicines to underserved populations.
    • The PPP model shows particular promise for tackling neglected tropical diseases.